الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Differentiated thyroid cancer (DTC) is the most common endocrine
malignancy and account for 90-95 per cent of all thyroid cancers. Its subtypes
include papillary thyroid carcinoma (PTC), follicular thyroid carcinoma and
Hürthle cell carcinoma.
Patients with differentiated thyroid carcinoma have an excellent
prognosis. The multimodal therapeutic approach is risk-adapted to achieve
optimal treatment of differentiated thyroid cancer (DTC) and to minimize
treatment-related morbidity. The treatment includes surgery (near-/total
thyroidectomy) usually followed by remnant ablation using radioiodine
according to the guidelines of the American Thyroid Association (ATA) and
European Association of Nuclear Medicine (EANM).
Risk factors and prognostic criteria for recurrent thyroid cancer differ
from those of primary disease. Survival in primary well differentiated thyroid
cancer is inversely related to both patient age and tumor size.
The serum thyroglobulin (Tg) concentration is commonly used as a
marker of thyroid tissue persistence/ recurrence after near-total thyroidectomy
in patients with negative Tg-antibody titers, with recombinant human thyroid
stimulating hormone (rhTSH)-stimulated Tg levels >2.5 ng/mL as the optimal
level for future recurrence.
We aimed to evaluate frequency and factors of recurrence of well
differentiated thyroid carcinoma after optimized surgery.
This is a prospective cohort study included 40 patients with recurrent
well deferentiated thyroid carcinoma.